Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.48 |
| ▸ | NEK2 | P51955 | 1/20 | 0.48 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.48 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 4/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
| ▸ | NSD2 | O96028 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29707613 | 0.87 | CHEK1 (0.60) | CHEK1NEK2LIMK1DYRK1ACLK4 | |
| SCHEMBL113870 | 0.87 | CHEK1 (0.60) | CHEK1NEK2LIMK1DYRK1ACLK4 | |
| Hydrochloric Acid SCHEMBL30129782 | 0.84 | CHEK1 (0.58) | CHEK1NEK2LIMK1DYRK1ACLK4 | |
| Hydrochloric Acid SCHEMBL6378551 | 0.84 | CHEK1 (0.58) | CHEK1NEK2LIMK1DYRK1ACLK4 | |
| Hydrochloric Acid SCHEMBL10431886 | 0.84 | CHEK1 (0.58) | CHEK1NEK2LIMK1DYRK1ACLK4 | |
| Hydrochloric Acid SCHEMBL4419467 | 0.84 | CHEK1 (0.58) | CHEK1NEK2LIMK1DYRK1ACLK4 | |
| Sulfuric Acid SCHEMBL1304808 | 0.79 | HSD17B10 (0.39) | GAAMAPTALDH1A1TSHRMAPK1 | |
| Sulfuric Acid SCHEMBL30532227 | 0.79 | HSD17B10 (0.39) | GAAMAPTALDH1A1TSHRMAPK1 | |
| Sulfuric Acid SCHEMBL28036340 | 0.77 | ALDH1A1 (0.47) | GAAMAPTALDH1A1SMN1; SMN2TP53 | |
| Sulfuric Acid SCHEMBL29647896 | 0.77 | ALOX15 (0.62) | GAAMAPTALDH1A1SMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190336462-A1 | USE OF HYDROGEN SULFIDE SYNTHESIS INHIBITORS FOR CANCER THERAPY | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-11-07 | — | — | US | disclosed |
| US-10335382-B2 | Use of hydrogen sulfide synthesis inhibitors for cancer therapy | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-07-02 | — | — | US | disclosed |
| EP-2764774-B1 | AQUATIC ORGANISM REARING SYSTEM AND AQUATIC ORGANISM REARING METHOD | JAPAN AGENCY MARINE EARTH SCI (JP) | 2018-03-28 | — | — | EP | disclosed |
| US-9868715-B2 | Apigenin analogs, compositions, and methods related thereto | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMS (US) | 2018-01-16 | — | — | US | disclosed |
| US-20170216323-A1 | Methods for Treating Viral Infections Using Hydrogen Sulfide Donors | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2017-08-03 | — | — | US | disclosed |
| US-20170204078-A1 | APIGENIN ANALOGS, COMPOSITIONS, AND METHODS RELATED THERETO | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-07-20 | — | — | US | disclosed |
| US-9616076-B2 | Methods for treating viral infections using hydrogen sulfide donors | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMS (US) | 2017-04-11 | — | — | US | disclosed |
| US-9603345-B2 | Aquatic organism rearing system and aquatic organism rearing method | JAPAN AGENCY FOR MARINE-EARTH SCIENCE AND TECHNOLOGY (JP) | 2017-03-28 | — | — | US | disclosed |
| EP-3096755-A2 | CYSTATHIONINE-(gamma)-LYASE (CSE) INHIBITORS FOR TREATING PAIN | Sova Pharmaceuticals, Inc. (US) | 2016-11-30 | — | — | EP | disclosed |
| US-9504701-B2 | Methods for treating viral infections using hydrogen sulfide donors | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-11-29 | — | — | US | disclosed |
| WO-2014201446-A2 | USE OF HYDROGEN SULFIDE SYNTHESIS INHIBITORS FOR THE THERAPY OF COLORECTAL CANCERS | HELLMICH MARK (US) | 2014-12-18 | — | — | WO | disclosed |
| US-20140245963-A1 | AQUATIC ORGANISM REARING SYSTEM AND AQUATIC ORGANISM REARING METHOD | JAPAN AGENCY FOR MARINE-EARTH SCIENCE AND TECHNOLOGY (JP) | 2014-09-04 | — | — | US | disclosed |
| EP-2764774-A1 | AQUATIC ORGANISM BREEDING SYSTEM AND METHOD FOR BREEDING SAME | Japan Agency for Marine-Earth Science and Technology (JP) | 2014-08-13 | — | — | EP | disclosed |
| EP-2760455-A1 | HYDROGEN SULFIDE RELEASING COMPOUNDS AND THEIR USE | The University Of Exeter (GB) | 2014-08-06 | — | — | EP | disclosed |
| WO-2014018569-A1 | CYSTATHIONINE-Y-GAMMA-LYASE (CSE) INHIBITORS | SOVA PHARMACEUTICALS, INC. (US) | 2014-01-30 | — | — | WO | disclosed |
| WO-2014018570-A1 | CYSTATHIONINE-Υ-LYASE (CSE) INHIBITORS | SOVA PHARMACEUTICALS, INC. (US) | 2014-01-30 | — | — | WO | disclosed |
| WO-2014018571-A2 | USE OF CSE INHIBITORS FOR THE TREATMENT OF CUTANEOUS INJURIES OR CONDITIONS AND SLEEP-RELATED BREATHING DISORDERS | SOVA PHARMACEUTICALS, INC. (US) | 2014-01-30 | — | — | WO | disclosed |
| WO-2013045951-A1 | HYDROGEN SULFIDE RELEASING COMPOUNDS AND THEIR USE | THE UNIVERSITY OF EXETER (GB) | 2013-04-04 | — | — | WO | disclosed |
| EP-2557921-A1 | METHODS FOR TREATMENT OF SLEEP-RELATED BREATHING DISORDERS | Johns Hopkins University (US) | 2013-02-20 | — | — | EP | disclosed |
| WO-2011130181-A1 | METHODS FOR TREATMENT OF SLEEP-RELATED BREATHING DISORDERS | JOHNS HOPKINS UNIVERSITY (US) | 2011-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190336462-A1 | USE OF HYDROGEN SULFIDE SYNTHESIS INHIBITORS FOR CANCER THERAPY | CBS, CTH, HCCS | CHEK1 126/4885NEK2 2100/4885LIMK1 3812/4885 |
| US-10335382-B2 | Use of hydrogen sulfide synthesis inhibitors for cancer therapy | CBS, CTH, HCCS | CHEK1 126/4885NEK2 2100/4885LIMK1 3812/4885 |
| US-20170204078-A1 | APIGENIN ANALOGS, COMPOSITIONS, AND METHODS RELATED THERETO | CBS, CTH, PTGIS | CHEK1 1203/4885NEK2 4608/4885LIMK1 3512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.